CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 1,000,000	$ 750,000
Operating expenses:
Consulting expense	547,933	1,469,171
General and administrative expense	379,424	359,259
Clinical trials	332,289	0
Research and development	197,406	321,938
Total operating expense	(1,457,052)	(2,150,368)
Income (loss) from operations	(457,052)	(1,400,368)
Other income (expense):
Interest income	12	5
Interest expense	(48,044)	(269,382)
Finance costs	(151,150)	(19,411)
Gain on debt forgiveness	5,000	151,308
Other expense	0	(369)
Original interest debt discount	(287,979)	(67,250)
Gain on change in fair value of derivative liabilities	468,823	646,705
Total other income (expense)	(13,338)	441,601
Net income (loss) before income tax	(470,390)	(958,767)
Income tax	0	0
Net income loss	$ (470,390)	$ (958,767)
Net income (loss) per share, basic and diluted	$ (0.00)	$ (0.01)
Weighted average number of shares outstanding, basic and diluted	107,741,761	72,342,193